Format

Send to:

Choose Destination
See comment in PubMed Commons below
Indian J Palliat Care. 2013 Jan;19(1):58-63. doi: 10.4103/0973-1075.110239.

A modified method for reducing renal injury in zoledronic Acid treatment of hypercalcemia and adverse skeletal events.

Author information

  • 1Department of Nuclear Medicine, Cancer Institute and Hospital of Tianjin Medical University, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.

Abstract

AIMS:

In this paper, we have reported a previously undescribed risk factor of deterioration of renal function in zoledronic acid treatment of skeletal metastasis - high serum calcium level. Based on this consideration, a modified method of treatment of hypercalcemia (HCM) with zoledronic acid is suggested in this paper.

MATERIAL AND METHODS:

Bone scan findings of 1090 cancer patients were analyzed, of which 26 had intense renal parenchymal uptake as a result of HCM or bone metastases. Subsequently, a total of 56 bone metastases patients with zoledronic acid treatment were divided into three groups: HCM group who were pre-treated to normal serum calcium level (13 patients), HCM group (19 patients), and normal serum calcium group (24 patients).

RESULTS:

More patients with intense renal parenchymal uptake were hyperglycemic, statistically significantly (18/26 versus 19/1064, P = 2.1, E-78). No more patients with intense renal parenchymal uptake were associated with bone metastases (14/26 versus 438/1064, P = 0.20). Subsequently, more HCM patients receiving zoledronic acid treatment showed renal injury compared to patients with normal serum calcium level (5/15 versus 2/24, P < 0.05) and HCM patients with pre-treatment to normal serum calcium level (5/15 versus 1/17, P < 0.05).

CONCLUSIONS:

Intense renal parenchymal uptake of bisphosphonates is closely related to HCM rather than to bone metastases in cancer patients. The serum calcium should be measured and reduced to normal level before zoledronic acid is used in managements of adverse skeletal events in order to decrease the risk of renal injury.

KEYWORDS:

Bone metastases; Hypercalcemia; Renal injury; Zoledronic acid

PMID:
23766597
[PubMed]
PMCID:
PMC3680841
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
    Loading ...
    Write to the Help Desk